Editorial Comment from Dr Yuasa to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
- PMID: 29764004
- DOI: 10.1111/iju.13699
Editorial Comment from Dr Yuasa to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
Comment on
-
Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.Int J Urol. 2018 Jun;25(6):596-603. doi: 10.1111/iju.13574. Epub 2018 May 13. Int J Urol. 2018. PMID: 29756394
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources